Implanting the seeds
of medical innovation

From science
to life science

at Every Step

Medinol Group

Since 1992, our in-house research, development, and manufacturing have continuously raised the bar for revolutionary interventional cardiology products, constantly stretching the limits of innovation.

Structural Heart
structural heart 1
Valve Medical
Stenting and Catheterization
FV L04.2 MDL354422 Elunir2022 Update zeroBG
Implantable Microsensors
microsensor 1
Microtech Medical


Our pioneering cardiovascular intervention technology continues to demonstrate extraordinary clinical results, and our products constantly stretch the limits of medical science.


Ridaforolimus Eluting Coronary Stent System
Optimized stent deliverability and conformability with a metal spring tip.
Read More


Ridaforolimus Eluting Coronary Stent System
Redefining stent deliverability and visibility for fast and accurate implantation.
Read More

Product Pipeline

Our uncompromising devotion to clinical achievement powers the creation of our products, shapes our roadmap and drives the growth of our intellectual property portfolio.


Read More
Drug-eluting Hybrid Scaffold

Investigational device, restricted to investigational use only. Not available for sale.


Read More
An Unfracturable SFA DES, Delivering Therapeutic Levels of Limus

Investigational device, restricted to investigational use only. Not available for sale.


Read More
Revolutionizing TAVR With a Modular Device

Investigational device, restricted to investigational use only. Not available for sale.

Microtech Sensors

Read More
Sub-millimeter passive, implantable sensors

Investigational device, restricted to investigational use only. Not available for sale.

Medinol Group

At a Glance

Research & Development
The Medinol's R&D team is diverse and capable of supporting various knowledge areas including exotic metals, drugs, and polymers, as well as the development of unique medical device manufacturing equipment. Read More
Clinical Trials
The Medinol's Clinical Department conducts successful global clinical trials, advancing medicine and providing state-of-the-art treatments with commitment to patient safety. Read More
Quality Control & Regulatory Affairs
The Medinol's Quality Management System ensures our products meet the highest safety, efficacy, and reliability standards, using a risk-based approach to proactively address issues and continuously improve. Read More
The Medinol Group designs and manufactures high-quality stents using innovative techniques and materials to improve patient outcomes. Our expert team provides customized solutions that meet customer needs. Read More

Latest News

Latest News
May 23, 2024
CE Approval for Medinol’s EluNIR-PERL™ Drug-Eluting Stent System

We are thrilled to announce that our innovative EluNIR-PERL™ DES has received CE approval! This marks a significant milestone in our commitment to advancing cardiovascular care and offering pioneering solutions to patients worldwide.

Read More
May 20, 2024
Dr. Raj Dave of Cardiovascular Experts of PA implanted the EluNIR - PERL DES

Dr. Dave noted, “The platinum marker on EluNIR – PERL allows accurate and precise placement in the most challenging coronary anatomy.”

A big thanks to the team at Cardiovascular Experts of PA and CoSo Health for helping patients and saving lives through innovative technology.

CoSo Health partners with Medinol to bring Elunir – PERL to hospitals and ASCs throughout the U.S. and Brazil.

Read More
April 25, 2024
FDA Approves Early Feasibility Study for our Groundbreaking ChampioNIR™ Drug-Eluting Peripheral Stent System

This is a significant milestone in our mission to bring advanced solutions for treating peripheral artery disease.

The EFS will allow us to evaluate the safety and performance of this novel stent technology in a clinical setting. We’re grateful for this opportunity to further our research and development efforts.

Read More
October 24, 2023
Medinol Receives FDA Approval for Next Generation EluNIR-PERL™ Drug-Eluting Coronary Stent System

Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL™ drug-eluting stent (DES) for the treatment of coronary artery disease.

Read More
August 18, 2023
Clinical considerations during spontaneous coronary artery dissection in the post-partum period: a case report

Emotional Case Report that was published in the European Society of Cardiology, European Heart Journal on 18 August 2023: “Clinical considerations during spontaneous coronary artery dissection in the post-partum period: a case report.”

Read More
June 8, 2023
TVT Conference - Valve Medical, First-in-Human TAVI Implant

Valve medical latest achievement was presented at TVT Summit 2023.
TVT Innovation III: Transcatheter Aortic Valve Replacement – Innovation & Clinical Science

Featured Technological Trends: New Generation TAVR Technologies
First-in-Human GEMINUS TAVI Implant: An Ultra-Low Profile Modular TAVI System
Lecturer: Eberhard Grube, MD


Read More
May 31, 2023
Valve Medical Announces Successful First-in-Human Implantation of Ultra-low Profile TAVR Valve in Israel

Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world’s first modular valve.

Read More
May 31, 2023
CTO Live Cases

We were proud to participate with our EluNIR DES System in the CTO Live Cases from 9 international centers with 26 expert interventional cardiologists on May 31st, 2023.

Read More
May 29, 2023
UP NEXT summit, Sourasky Medical

 Dr. Yoram Richter Medinol’s CEO joined a session on “Innovative stents and valves in cardiac disease” at the UP NEXT summit, Sourasky Medical Center (Ichilov), The first Israeli conference for technological innovation in healthcare.

Read More
May 25, 2023
Pavlodar City Cardio Center Conference

Our EluNIR DES System was presented last week at the Pavlodar City Cardio Center Conference, Kazakhstan, by our respected local distributor Dan Med LLP.

Read More
May 18, 2023
Medinol - PCR 2023

On PCR 2023, Prof. Maayan Konigstein, Director Interventional Cardiology Catheterization Unit, Tel Aviv Sourasky Medical Center – Ichilov in a lecture on: “The Medinol IoNir hybrid coronary DES system”.

Read More
May 5, 2020
Medinol Completes Enrollment of EluNIR-HBR Study

Deliverability of EluNIR™ in complex patient anatomy demonstrated during first commercial cases at Columbia University Medical Center and Piedmont Heart Institute

Read More

Accessibility Toolbar